[1]曹琳 郑仁东 曹雯 许娟 孙洪平 刘超.甲状腺相关性眼病治疗新进展[J].国际内分泌代谢杂志,2019,39(01):25-28,33.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
　Cao Lin,Zheng Rendong,Cao Wen,et al.Update on the management of thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2019,39(01):25-28,33.[doi:10.3760/cma.j.issn.1673-4157.2019.01.006]
点击复制

甲状腺相关性眼病治疗新进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年01期
页码:
25-28,33
栏目:
综述
出版日期:
2019-01-20

文章信息/Info

Title:
Update on the management of thyroid-associated ophthalmopathy
作者:
曹琳 郑仁东 曹雯 许娟 孙洪平 刘超
南京中医药大学附属中西医结合医院内分泌代谢病院区 210028
Author(s):
Cao Lin;  Zheng Rendong;  Cao Wen;  Xu Juan;  Sun Hongping;  Liu Chao
Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
甲状腺相关性眼病;  糖皮质激素;  放射性疗法;  眼眶减压术
Keywords:
Thyroid ophthalmopathy;  Glucocorticoid;  Radiotherapy;  Orbital decompression surgery
DOI:
10.3760/cma.j.issn.1673-4157.2019.01.006
摘要:
甲状腺相关性眼病是一种器官特异性自身免疫性疾病,发病机制不明。针对甲状腺和眼眶共同抗原的自身免疫反应在其发病中起重要作用。轻度突眼者可采用一般措施控制症状和体征,但中重度活动期需要采用糖皮质激素、球后照射两种主要方法。非活动期眼眶减压术是首选。对传统治疗无效的患者还可以采用其他措施如免疫抑制剂、生长抑素类似物、血浆置换、静脉免疫球蛋白、抗细胞因子等。
Abstract:
Thyroid-associated ophthalmopathy is an autoimmune disorder, but its pathogenesis is not completely understood. Autoimmunity against putative antigens shared by the thyroid and the orbit plays a role in the pathogenesis of the disease. Supportive approaches can control symptoms and signs in mild cases. In severe active disease, glucocorticoid and/or orbital radiotherapy are the main treatments. In inactive disease with proptosis, orbital decompression can be preferred. Miscellaneous treatments such as immunosuppressive drugs, somatostatin analogs, plasmapheresis, intravenous immunoglobulins and anticytokine therapies have been used in patients who are resistant to conventional treatments.

参考文献/References:

[1] Smith TJ,Hegedüs L.Graves' disease[J].N Engl J Med,2016,375(16):1552-1565.DOI:10.1056/NEJMra1510030.
[2] Pujol-Borrell R,Giménez-Barcons M,Marín-Sánchez A,et al.Genetics of Graves' disease: special focus on the role of TSHR gene[J].Horm Metab Res,2015,47(10):753-766.DOI:10.1055/s-0035-1559646.
[3] Wang Y,Smith TJ.Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy[J].Invest Ophthalmol Vis Sci,2014,55(3):1735-1748.DOI:10.1167/iovs.14-14002.
[4] Wiersinga WM.Thyroid autoimmunity[J].Endocr Dev,2014,26:139-157.DOI:10.1159/000363161.
[5] Bartalena L,Baldeschi L,Boboridis K,et al.The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J].Eur Thyroid J,2016,5(1):9-26.DOI:10.1159/000443828.
[6] Walsh JP,Dayan CM,Potts MJ. Radioiodine and thyroid eye disease[J].BMJ,1999,319(7202):68-69.
[7] Bricen～o CA,Gupta S,Douglas RS.Advances in the management of thyroid eye disease[J].Int Ophthalmol Clin,2013,53(3):93-101.DOI:10.1097/IIO.0b013e318293c44e.
[8] Marcocci C,Kahaly GJ,Krassas GE,et al.Selenium and the course of mild Graves' orbitopathy[J].N Engl J Med,2011,364(20):1920-1931.DOI:10.1056/NEJMoa1012985.
[9] Dehina N,Hofmann PJ,Behrends T,et al.Lack of association between selenium status and disease severity and activity in patients with Graves' ophthalmopathy[J].Eur Thyroid J,2016,5(1):57-64.DOI:10.1159/000442440.
[10] Currò N,Covelli D,Vannucchi G,et al.Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy[J].Thyroid,2014,24(5):897-905.DOI:10.1089/thy.2013.0445.
[11] Hahn E,Laperriere N,Millar BA,et al.Orbital radiation therapy for Graves' ophthalmopathy: measuring clinical efficacy and impact[J].Pract Radiat Oncol,2014,4(4):233-239.DOI:10.1016/j.prro.2014.02.008.
[12] Stan MN,Garrity JA,Bahn RS.The evaluation and treatment of Graves' ophthalmopathy[J].Med Clin North Am,2012,96(2):311-328.DOI:10.1016/j.mcna.2012.01.014.
[13] Ye X,Bo X,Hu X,et al.Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy[J].Clin Endocrinol(Oxf),2017,86(2):247-255.DOI:10.1111/cen.13170.
[14] Kahaly GJ,Pitz S,Hommel G,et al.Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy[J].J Clin Endocrinol Metab,2005,90(9):5234-5240.DOI:10.1210/jc.2005-0148.
[15] Wémeau JL,Caron P,Beckers A,et al.Octreotide(long-acting release formulation)treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study[J].J Clin Endocrinol Metab,2005,90(2):841-848.DOI:10.1210/jc.2004-1334.
[16] Pilarska K,Kulig G.Lanreotide in the treatment of thyroid orbitopathy[J].Przegl Lek,2004,61(8):845-847.
[17] Hiromatsu Y,Yang D,Miyake I,et al. Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from patients with thyroid-associated ophthalmopathy[J].J Clin Endocrinol Metab,1998,83(1):121-124.
[18] Seppel T,Schlaghecke R,Becker A,et al. High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy[J].Clin Exp Rheumatol,1996,14(Suppl 15):S109-S114.
[19] Berlin G,Hjelm H,Liedén G,et al.Plasma exchange in endocrine ophthalmopathy[J].J Clin Apher,1990,5(4):192-196.
[20] Hegedüs L,Smith TJ,Douglas RS,et al.Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab[J].Clin Endocrinol(Oxf),2011,74(1):1-8.DOI:10.1111/j.1365-2265.2010.03806.x.
[21] Stan MN,Garrity JA,Carranza Leon BG,et al.Randomized controlled trial of rituximab in patients with Graves' orbitopathy[J].J Clin Endocrinol Metab,2015,100(2):432-441.DOI:10.1210/jc.2014-2572.
[22] Salvi M.Immunotherapy for Graves' ophthalmopathy[J].Curr Opin Endocrinol Diabetes Obes,2014,21(5):409-414.DOI:10.1097/MED.0000000000000097.
[23] Khanna D,Chong KK,Afifiyan NF,et al.Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy[J].Ophthalmology,2010,117(1):133-139.e2.DOI:10.1016/j.ophtha.2009.05.029.
[24] McCoy AN,Kim DS,Gillespie EF,et al.Rituximab(Rituxan)therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+)T cells[J].J Clin Endocrinol Metab,2014,99(7):E1294-E1299.DOI:10.1210/jc.2013-3207.
[25] Pérez-Moreiras JV,Alvarez-López A,Gómez EC.Treatment of active corticosteroid-resistant Graves' orbitopathy[J].Ophthalmic Plast Reconstr Surg,2014,30(2):162-167.DOI:10.1097/IOP.0000000000000037.
[26] Tsui S,Naik V,Hoa N,et al.Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease[J].J Immunol,2008,181(6):4397-4405.
[27] Krieger CC,Place RF,Bevilacqua C,et al.TSH/IGF-1 receptor cross talk in Graves' ophthalmopathy pathogenesis[J].J Clin Endocrinol Metab,2016,101(6):2340-2347.DOI:10.1210/jc.2016-1315.
[28] Smith TJ,Kahaly GJ,Ezra DG,et al.Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[29] Jellema HM,Merckel-Timmer E,Kloos R,et al.Quality of life improves after strabismus surgery in patients with Graves' orbitopathy[J].Eur J Endocrinol,2014,170(5):785-789.DOI:10.1530/EJE-13-0973.
[30] Bartalena L,Marcocci C,Bogazzi F,et al.Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy[J].N Engl J Med,1998,338(2):73-78.

相似文献/References:

[1]孙红爽,乜春城,朱小丽,等.11β-HSD1在糖皮质激素联合高脂喂养 大鼠胰岛素抵抗中的作用[J].国际内分泌代谢杂志,2016,36(01):14.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
　Sun Hongshuang*,Nie Chuncheng,Zhu Xiaoli,et al.Effects of 11β-hydroxysteroid dehydrogenase type 1 on insulin resistance in rats induced by glucocorticoid and high fat diet[J].International Journal of Endocrinology and Metabolism,2016,36(01):14.[doi:10.3760/cma.j.issn.1673-4157.2016.01.004]
[2]余静雯 胡欣 叶向荣 陈彦 刘超.2021年欧洲甲状腺学会/欧洲Graves眼病专家组Graves眼病管理指南:解读与思考[J].国际内分泌代谢杂志,2022,42(04):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
　Yu Jingwen,Hu Xin,Ye Xiangrong,et al.Interpretation and discussion of the 2021 European Thyroid Association/European Group on Graves'Orbitopathy Guidelines for the Management of Graves' Orbitopathy[J].International Journal of Endocrinology and Metabolism,2022,42(01):250.[doi:10.3760/cma.j.cn121383-20211003-10002]
[3]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
　Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(01):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
[4]陆晨雅,陈国芳,徐书杭,等.甲状腺相关性眼病处理的新视角:局部注射疗法[J].国际内分泌代谢杂志,2023,43(02):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
　Lu Chenya,Chen Guofang,Xu Shuhang,et al.Therapy insight: local injections for the treatment of thyroid associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2023,43(01):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
[5]郭伟红,何庆.21-羟化酶缺陷症的围妊娠期管理研究进展[J].国际内分泌代谢杂志,2023,43(02):128.[doi:10.3760/cma.j.cn121383-20211202-12006]
　Guo Weihong,He Qing..Peripregnancy management of 21-hydroxylase deficiency[J].International Journal of Endocrinology and Metabolism,2023,43(01):128.[doi:10.3760/cma.j.cn121383-20211202-12006]

备注/Memo

备注/Memo:
通信作者:刘超,Email:liuchao@nfmcn.com
Corresponding author: Liu Chao, Email:liuchao@nfmcn.com
更新日期/Last Update: 2019-01-20